News|Articles|November 20, 2026

Rotavirus Vaccine Recommendation Change May Undo Decades of Progress

Fact checked by: Abigail Brooks, MA

Rotavirus vaccine uptake declines under shared clinical decision-making could add up to 4500 infant hospitalizations per birth cohort, a new model projects.

Shifting rotavirus vaccination from a routine recommendation to shared clinical decision-making (SCDM) could lead to as many as 4500 additional hospitalizations and 13,200 additional emergency department (ED) visits for acute gastroenteritis (AGE) among US children younger than 2 years in a single annual birth cohort, according to a new decision analytical modeling study.¹

“Even modest reductions in vaccination uptake may result in increased morbidity and increased clinical and economic burdens on the health care system and society,” wrote Anne M. Butler, PhD, MS, of the Division of Infectious Diseases at Washington University School of Medicine in St Louis, Missouri, and colleagues wrote in the research letter published in JAMA Network Open. “Revisions from routine to SCDM rotavirus vaccination recommendations warrant full consideration of the potential negative effects on public health and health care expenditures.”1

Excess encounters would add an estimated $34.5 million to $103.5 million in health care expenditures from a societal perspective for each birth cohort, and the burden would compound with every subsequent cohort, reported Butler and colleagues. The investigators concluded that even modest declines in vaccine uptake could begin to undo decades of progress in preventing rotavirus disease.¹

How Effective Has Rotavirus Vaccination Been in the US?

Before vaccines were available, approximately 80% of US children were infected with rotavirus by age 5 years, accounting for more than 55,000 hospitalizations and more than 200,000 ED visits each year, at a cost exceeding $1 billion annually.¹˒² The first rotavirus vaccine was licensed by the US Food and Drug Administration in 1998 but withdrawn in 1999 after reports of intussusception.¹ Later trials incorporated safety monitoring for intussusception, leading to licensure of a 3-dose pentavalent rotavirus vaccine (RotaTeq; Merck) in 2006 and a 2-dose monovalent rotavirus vaccine (Rotarix; GlaxoSmithKline) in 2008.¹

The Advisory Committee on Immunization Practices (ACIP) recommended routine rotavirus vaccination of US infants in 2006, and the recommendation became official policy of the Centers for Disease Control and Prevention (CDC).¹˒² In the decade that followed, routine vaccination reduced rotavirus hospitalizations by approximately 80% and ED visits by 57%, shifted seasonal activity from an annual to a biennial pattern, and reduced community transmission among unvaccinated individuals.¹˒³

What Changed in the CDC Rotavirus Vaccine Recommendation in 2026?

On January 5, 2026, the CDC rescinded routine recommendations for several pediatric immunizations, including rotavirus, and replaced them with SCDM between clinicians and patients or their parents or guardians.¹ The American Academy of Pediatrics (AAP) sued to reinstate the prior schedule. On March 16, 2026, a federal judge in the US District Court for the District of Massachusetts temporarily blocked the changes, finding that the federal government had not based its decisions on science, and restored the routine rotavirus recommendation.¹˒⁴ The federal government appealed the ruling to the US Court of Appeals for the First Circuit on April 29, 2026.⁴

Butler and colleagues described the resulting misalignment between the CDC and AAP schedules as unprecedented and said it raised important questions about the public health consequences of revising the federal schedule.¹

How Did Researchers Model the Impact of Shared Clinical Decision-Making?

The investigators modeled 3 scenarios in which an SCDM recommendation would reduce vaccine access and uptake, shifting 10%, 20%, or 30% of infants from fully vaccinated to unvaccinated.¹ Current uptake was defined as 71% fully vaccinated, 15% partially vaccinated, and 14% unvaccinated.¹

The model applied 2-year risks of AGE-related hospitalization of 47, 67, and 88 per 10,000 infants who were fully vaccinated, partially vaccinated, and unvaccinated, respectively, and 2-year risks of AGE-related ED visits of 315, 434, and 436 per 10,000.¹ These estimates were drawn from a prior study of 1,147,699 commercially insured infants born in the US between 2009 and 2016.¹

Costs were calculated in 2025 US dollars from a societal perspective, including direct medical and indirect costs, at $19,675 per AGE-related hospitalization and $1206 per AGE-related ED visit, assuming 3,622,673 annual US births.¹ The model accounted only for the direct effects of vaccination. The authors also developed an online tool that allows users to test how changes in these assumptions affect the projections.¹

How Many More Infant Hospitalizations Could Lower Rotavirus Vaccine Uptake Cause?

Under current vaccination uptake, the model projected that an annual US birth cohort would experience more than 20,200 AGE-related hospitalizations and 126,800 AGE-related ED visits by age 2 years.¹

If 10% to 30% of infants shifted from fully vaccinated to unvaccinated under an SCDM recommendation, those children would experience an additional 1500 to 4500 hospitalizations and 4400 to 13,200 ED visits for AGE by age 2 years.¹ These preventable encounters were associated with an additional $34.5 million to $103.5 million in health care expenditures.¹ Because the figures reflect a single birth cohort, the excess burden and costs would accumulate with each subsequent year of reduced uptake.¹

Why Might These Estimates Understate the True Rotavirus Burden?

The investigators characterized their projections as the minimum number of additional AGE-related encounters associated with moving from a routine to an SCDM recommendation.¹ The model did not account for secondary or indirect protection, which may reduce rotavirus burden among unvaccinated children by 50%.¹˒⁵ Projections were limited to children younger than 2 years, the age group with the highest AGE-related health care burden, and excluded outpatient visits and their associated costs.¹

In addition, encounters coded as AGE have low sensitivity, potentially underestimating the true disease burden.¹ The risk estimates were derived from a commercially insured population, which has a lower risk of AGE-related health care use than publicly insured children, who represent approximately one-third of US children.¹ The baseline estimate of full vaccination was also at the low end of published estimates, which the authors noted could underestimate absolute burden but would not necessarily underestimate the excess burden associated with a shift to SCDM.¹

What Should Primary Care Clinicians Know About Rotavirus Vaccination Now?

The authors concluded that any revision from routine to SCDM recommendations for rotavirus vaccination warrants full consideration of the potential negative effects on public health and health care expenditures.¹

Under the CDC schedule restored by the court, rotavirus vaccine is administered orally as a 2-dose series at ages 2 and 4 months (monovalent) or a 3-dose series at ages 2, 4, and 6 months (pentavalent), and the maximum age for the first dose is 14 weeks, 6 days.¹˒⁶ Because of that narrow window, missed or delayed well-child visits in early infancy can close the opportunity for vaccination entirely.⁶

References

  1. Butler AM, Panozzo CA, Boutzoukas AE, Brookhart MA. Shared clinical decision-making for rotavirus vaccination and future health care use in infants. JAMA Netw Open. 2026;9(10):e2640546. doi:10.1001/jamanetworkopen.2026.40546
  2. Cortese MM, Parashar UD. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2009;58(RR-2):1-25.
  3. Pindyck T, Tate JE, Parashar UD. A decade of experience with rotavirus vaccination in the United States – vaccine uptake, effectiveness, and impact. Expert Rev Vaccines. 2018;17(7):593-606. doi:10.1080/14760584.2018.1489724
  4. Forsberg VC, Mickler AK, Sekar K. The 2026 childhood immunization schedule. Congressional Research Service. Report R48982. June 11, 2026. Accessed November 20, 2026. https://www.congress.gov/crs-product/R48982
  5. Rosettie KL, Vos T, Mokdad AH, et al. Indirect rotavirus vaccine effectiveness for the prevention of rotavirus hospitalization: a systematic review and meta-analysis. Am J Trop Med Hyg. 2018;98(4):1197-1201. doi:10.4269/ajtmh.17-0705
  6. Recommended child and adolescent immunization schedule for ages 18 years or younger, United States, 2025. Centers for Disease Control and Prevention. Accessed November 20, 2026. https://www.cdc.gov/vaccines/hcp/imz-schedules/downloads/child/0-18yrs-child-combined-schedule.pdf

Related to this article